Skip to main content

Top Menu

  • Contact
  • Media
  • Careers
  • Staff
  • About Us
    • About CCTG
    • CCTG Strategic Plan 2022-2027
    • Committee Leadership
    • CCTG Scientific Leadership
    • CCTG Management
    • Careers at CCTG
    • CCTG policies
    • Contact us
  • Patients & Families
    • Patients & Families
    • Patient Representatives Committee
    • Patients as research partners
    • Resources for patients & families
    • Clinical trials - public
  • Disease Site Listings - Public

    Disease Site Listings - Public

    • All
    • Brain
    • Breast
    • Gastro-Intestinal
    • Genito-Urinary
    • Gynecologic
    • Head & Neck
    • Hematologic
    • IND
    • Lung
    • Melanoma
    • Multi-Site
    • Sarcoma
    • Symptom Control
  • Disease Site Listings - Members

    Disease Site Listings - Members

    • All
    • Brain
    • Breast
    • Gastro-Intestinal
    • Genito-Urinary
    • Gynecologic
    • Head & Neck
    • Hematologic
    • IND
    • Lung
    • Melanoma
    • Sarcoma
    • Symptom Control
    • Multi-Site
  • Clinical Trials
    • All Trials
    • Brain
    • Breast
    • Gastro-Intestinal
    • Genito-Urinary
    • Gynecologic
    • Head & Neck
    • Hematologic
    • IND
    • Lung
    • Melanoma
    • Sarcoma
    • Symptom Control
    • Multi-Site
    • Clinical trials - overview
    • All Trials
    • Brain
    • Breast
    • Gastro-Intestinal
    • Genito-Urinary
    • Gynecologic
    • Head & Neck
    • Hematologic
    • IND
    • Lung
    • Melanoma
    • Sarcoma
    • Symptom Control
    • Multi-Site
    • Publications

    Mobile CCTG Clinical Trials

    • Member Trial Pages
    • Public Trial Pages
    • Publications

    CCTG MA41 Breast Cancer Study opens in Canada

    The purpose of this study is to test whether a new drug regimen will reduce the chances of side effects but be just as effective as the usual treatment for HER2-positive, ER-negative and node negative breast cancer. ​

    More >>

    Recently Activated Trials

    CRC10

    Colon Adjuvant Chemotherapy Based on Evaluation of Residual Disease

    More >>

    EN10

    Tailored Adjuvant Therapy in POLE-mutated and p53-wildtype/NSMP Early Stage Endometrial Cancer (RAINBO BLUE & TAPER)

    More >>

    I241

    A Liquid-biopsy Informed Platform Trial to Evaluate Treatment in CDK4/6-inhibitor Resistant ER+/HER2- Metastatic Breast Cancer

    More >>

    I241A

    Liquid-Biopsy Monitoring for Patients not yet Eligible for Screening and Enrollment

    More >>
  • Member Resources

    Member Links

    • Current trials
    • Disease site & IND committees
    • Standing committees
    • Leadership resources
    • Become a member
    • Funding information
    • Compliance & oversight
    • Audit, inspection & partner compliance
    • Generic protocols
    • Group newsletter: CCTG Connection
    • ID.me Resources
    • Help & Support
    • Terms of reference
    Oral presentation by Dr Laura Dawson at the ASCO Gastrointestinal Cancer Symposium 2023 of results for the Canadian Cancer Trials Group (CCTG) HE1

    Quality of life study shows radiation can improve pain management for liver cancer patients

    Oral presentation by Dr Laura Dawson at the ASCO Gastrointestinal Cancer Symposium 2023 of results for the CCTG HE1 phase III study of palliative radiation therapy for symptomatic hepatocellular carcinoma and liver metastases.

    More >>

    Planned Trials

    AL6

    MRD Driven Study of Venetoclax + Chemotherapy for Newly Diagnosed Younger Patients with Intermediate Risk AML

    ALC7

    Master Screening and Reassessment Protocol (MYELOMATCH) for the NCI myeloMATCH clinical trials

    ALC8

    Novel Therapeutics in Younger Patients with High-Risk AML (MM1YA-S01)

    ALC9

    Eradicating MRD in patients with AML prior to Stem Cell Transplant (ERASE)

    EN11

    RAINBO: Refining Adjuvant treatment IN endometrial cancer Based On molecular features. The MMRD-GREEN trial

    More >>

    GA4

    Paclitaxel and Ramucirumab +/- Zanidatamab in HER2 Postive Advanced Gastroesophageal Adenocarcinoma

    Disease Site Committees

    • Brain
    • Breast
    • Gastro-Intestinal
    • Gynecologic
    • Genito-Urinary
    • Head & Neck Working Group
    • Hematologic
    • IND
    • IND Executive
    • Lung Disease
    • Melanoma
    • Sarcoma
  • Meetings & Education
    • Spring meeting of participants
      • CCTG recognition awards
      • Maria Ricci Memorial Lecture
    • New investigator cancer trials practicum
    • New investigator clinical trials course
    • Fellowships
    • The Frances A Shepherd Award
    • Conference presentations
  • Search
  • Donate
  • Toolbox
    • Applications
    • >>  EDC (Medidata Rave)
    • >>  iMedidata
    • >>  Mango
    • >>  Ripple
    • >>  Lettuce
    • >>  Sprout (ePRO)
    • Exposure Reporting
    • >>  CTEP website
    • >>  CTCAE v5.0 booklet
    • >>  CTCAE v4.0 booklet
    • >>  CTCAE v3.0 booklet
    • >>  CTEP-AERS reporting
    • >>  EDC SAE (paper report)
    • >>  Pregnancy reporting form
    • >>  Exposure reporting form
    • Support
    • >>  Passwords management
    • >>  CCTG contacts
    • >>  Support information
    • Tissue Bank
    • >>  Tissue Bank
    • >>  Inventory
    • >>  Tissue research
    • Reports
    • >>  Accrual utility (Monthly site accrual)
    • >>  Safety reports
    • >>  Papaya
    • >>  Ethics
    • >>  Trial closure
    • Data Management
    • >>  Baseline symptoms & adverse events
    • >>  Concomitant medications template
    • >>  SI conversion table
    • >>  iRECIST & RECIST guidelines
    • Training
    • >>  NIH ethics training
    • >>  Division 5 part C
    • >>  Good clinical practice
    • >>  Site training
    • >>  Supplementary training
  • Contact Us
  • Media
  • Staff

  For important CCTG updates and general information: public updates | CCTG member updates

Staff Links

Email

  • Zimbra
  • Messenger Express (access your email prior to June 2012)

Intranet

  • CCTG Intranet
 

Instructions for Working at Home

  • Working at Home

File Sharing

  • Nextcloud
  • Partnerships 600+ trials in 40+ countries
  • IND Program 38+ years experience in 205+ drug trials
  • Tissue Bank 300,000+ samples from 120+ trials
  • Network 2100+ investigators at 85+ sites
  • Become a CCTG Investigator
CCTG Strategic Plan 2022-2027
CCTG Strategic Plan 2022-2027

Footer Menu

  • About us
  • Patients & Families
  • Clinical trials
  • Member resources
  • Meetings & Education
  • Publications
  • Toolbox
  • Contact us
  • Media centre
  • Staff
  • Careers

CANADIAN CANCER TRIALS GROUP

Cancer Research Institute
Queen's University

10 Stuart Street
Kingston, Ontario
Canada K7L 3N6

A NATIONAL PROGRAM OF THE:

 

OPERATIONS AND STATISTICAL CENTRE LOCATED AT:

PROUDLY AFFILIATED WITH:

As a national cooperative group, CCTG recognizes that Canada is situated on Indigenous lands, we acknowledge that the Operations and Statistics Centre, located at Queen’s University, is located on traditional Anishinaabe and Haudenosaunee Territory.
© Canadian Cancer Trials Group, 2021 | Terms & Conditions Facebook LinkedIn TwitterYouTube